Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Prednisolone Acetate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
Details : Pred Forte-Generic (prednisolone acetate) is a sterile, topical antiinflammatory agent and is indicated for treating steroid-responsive ocular inflammation.
Product Name : Pred Forte-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 12, 2025
Lead Product(s) : Prednisolone Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prednisolone Acetate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Launches First Generic of Pred Forte in the US
Details : Pred Forte-Generic (prednisolone acetate) is indicated for the treatment of steroid responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Product Name : Pred Forte-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2024
Lead Product(s) : Prednisolone Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prednisolone Acetate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives USFDA Approval for Prednisolone Acetate Ophthalmic Suspension USP
Details : Pred Forte-Generic (prednisolone acetate) is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Product Name : Pred Forte-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 08, 2024
Lead Product(s) : Prednisolone Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prednisolone Acetate
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Science in Vision | Imprimis Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Prophylactic Treatment: Lessdropsâ„¢ vs Standard Drops Regimen
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2018
Lead Product(s) : Prednisolone Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Science in Vision | Imprimis Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prednisolone Acetate
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : University of Toronto
Deal Size : Inapplicable
Deal Type : Inapplicable
Topical Use of Corticosteroid to Prevent Epiretinal Membrane Following Retinal Tear
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2015
Lead Product(s) : Prednisolone Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : University of Toronto
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Prednisolone Acetate
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 02, 2010
Lead Product(s) : Prednisolone Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable